Epithelial cell adhesion molecule‑targeting designed ankyrin repeat protein‑toxin fusion Ec1‑LoPE exhibits potent cytotoxic action in prostate cancer cells-Reference-Cited by-同舟云学术

Epithelial cell adhesion molecule‑targeting designed ankyrin repeat protein‑toxin fusion Ec1‑LoPE exhibits potent cytotoxic action in prostate cancer cells

Published:2022-03-18 Issue:5 Volume:47 Page:
ISSN:1021-335X
Container-title:Oncology Reports
language:
Short-container-title:Oncol Rep

Author:

Xu Tianqi¹,Liu Yongsheng¹,Schulga Alexey²,Konovalova Elena³,Deyev Sergey²,Tolmachev Vladimir¹,Vorobyeva Anzhelika¹

Affiliation:

1. Department of Immunology, Genetics and Pathology, Uppsala University, SE-75185 Uppsala, Sweden

2. Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, National Research Tomsk Polytechnic University, 634050 Tomsk, Russia

3. Molecular Immunology Laboratory, Shemyakin‑Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,General Medicine

Reference52 articles.

1. Novel insights into the management of oligometastatic prostate cancer: A comprehensive review;Battaglia;Eur Urol Oncol,2019

2. Androgen receptor signaling in prostate cancer and therapeutic strategies;Jacob;Cancers (Basel),2021

3. A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer;Sadaghiani;Eur Urol,2021

4. Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy;Thang;Eur Urol Oncol,2019

5. Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy;Rosar;Theranostics,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Probing the Relationship Between the Human Gut Microbiome and Prospects of Prostate Cancer: A Systematic Review;Cureus;2023-08-21

2. Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model;International Journal of Molecular Sciences;2023-02-02

3. Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting;International Journal of Molecular Sciences;2023-02-02

4. Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart;Pharmaceutics;2022-08-02